Equity Overview
Price & Market Data
Price: $2.14
Daily Change: -$0.015 / 0.70%
Range: $2.01 - $2.18
Market Cap: $568,204,608
Volume: 439,181
Performance Metrics
1 Week: -8.26%
1 Month: 75.95%
3 Months: 14.79%
6 Months: -25.21%
1 Year: -50.19%
YTD: -8.66%
Company Details
Employees: 647
Sector: Health technology
Industry: Biotechnology
Country: United Kingdom
Details
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.